US · BSX
Boston Scientific Corporation
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Marlborough, MA 01752-1234
- Website
- bostonscientific.com
Price · as of 2025-12-31
$56.50
Market cap 114.04B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $67.26 | +19.04% |
| Intrinsic Value(DCF) | $50.27 | -11.03% |
| Graham-Dodd Method(GD) | $13.77 | -75.63% |
| Graham Formula(GF) | $52.77 | -6.6% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $5.95 | $27.29 | $0.39 | $2.52 | $1.71 |
| 2012 | $7.49 | $25.19 | $0.00 | $0.00 | $0.00 |
| 2013 | $13.70 | $30.06 | $0.00 | $0.18 | $0.00 |
| 2014 | $16.61 | $33.23 | $0.17 | $0.26 | $0.00 |
| 2015 | $18.05 | $31.97 | $0.00 | $0.00 | $0.00 |
| 2016 | $24.64 | $37.52 | $0.81 | $1.32 | $5.06 |
| 2017 | $28.54 | $37.62 | $8.16 | $0.39 | $1.18 |
| 2018 | $39.51 | $41.59 | $7.39 | $6.64 | $19.79 |
| 2019 | $37.60 | $45.93 | $5.47 | $19.55 | $57.19 |
| 2020 | $38.85 | $39.81 | $0.00 | $3.21 | $0.00 |
| 2021 | $41.70 | $45.56 | $0.11 | $6.33 | $19.93 |
| 2022 | $46.48 | $44.37 | $0.32 | $5.12 | $7.05 |
| 2023 | $67.66 | $55.67 | $0.00 | $8.56 | $21.71 |
| 2024 | $99.13 | $69.71 | $4.52 | $9.48 | $31.45 |
| 2025 | $76.22 | $67.26 | $36.50 | $13.77 | $52.77 |
AI valuation
Our deep-learning model estimates Boston Scientific Corporation's (BSX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $67.26
- Current price
- $56.50
- AI upside
- +19.04%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$50.27
-11.03% upside
Graham-Dodd
$13.77
-75.63% upside
Graham Formula
$52.77
-6.6% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BSX | Boston Scientific Corpora… | $56.50 | 114.04B | +19% | -11% | -76% | -7% | 39.02 | 4.66 | 5.62 | 33.01 | 70.68 | -105.55 | 69.01% | 19.78% | 14.38% | 12.57% | 10.11% | 6.96% | 0.51 | 11.38 | 1.62 | 0.91 | 2.78 | 5520.00% | 1987.00% | 3830.00% | 3.24% | 0.83 | 10.90% | 0.00% | 0.00% | 0.32% | 31.03 | 33.68 | 6.14 | 4.56 |
| ABT | Abbott Laboratories | $116.32 | 202.45B | -26% | -58% | — | -57% | 30.56 | 3.82 | 4.50 | 17.79 | — | 8.83 | 55.51% | 18.16% | 14.72% | 13.07% | 10.95% | 7.76% | 0.29 | 23.60 | 1.58 | 1.02 | 0.57 | -5131.00% | 567.00% | 1644.00% | 3.71% | 0.58 | 13.06% | 2.06% | 63.10% | 3.07% | 25.53 | 27.79 | 4.64 | 5.28 |
| AMGN | Amgen Inc. | $387.96 | 209.14B | -9% | -34% | — | -35% | 26.91 | 23.97 | 5.65 | 15.97 | 30.50 | -6.42 | 70.80% | 29.06% | 20.99% | 106.10% | 16.96% | 8.45% | 6.31 | 3.88 | 1.14 | 0.73 | 2.87 | 8823.00% | 992.00% | -2207.00% | 3.90% | 0.39 | 14.98% | 2.47% | 66.50% | 3.75% | 23.70 | 31.23 | 6.89 | 2.36 |
| DHR | Danaher Corporation | $210.64 | 148.95B | -10% | -58% | -90% | -73% | 40.32 | 2.77 | 5.93 | 22.97 | — | -17.28 | 60.93% | 20.91% | 14.71% | 7.08% | 6.70% | 4.49% | 0.35 | 19.38 | 1.87 | 1.25 | 1.99 | -473.00% | 290.00% | -68.00% | 3.61% | 0.94 | 8.03% | 0.60% | 24.30% | 3.59% | 31.05 | 30.32 | 6.49 | 4.20 |
| GILD | Gilead Sciences, Inc. | $148.95 | 184.8B | -18% | -32% | — | -52% | 21.93 | 8.25 | 6.34 | 18.54 | 1.30 | -69.80 | 86.69% | 40.14% | 28.90% | 40.57% | 28.89% | 14.42% | 1.09 | 11.54 | 1.68 | 1.31 | 1.57 | 168421.00% | 240.00% | -824.00% | 5.07% | 0.85 | 26.61% | 2.14% | 47.00% | 3.17% | 16.98 | 21.22 | 6.81 | 4.40 |
| HCA | HCA Healthcare, Inc. | $529.70 | 118.45B | -26% | -56% | -86% | -18% | 18.12 | -20.40 | 1.63 | 11.03 | 62.49 | -7.53 | 41.50% | 15.83% | 8.97% | -159.14% | 22.59% | 11.28% | -8.33 | 5.32 | 0.83 | 0.73 | 3.15 | 2900.00% | 708.00% | 3641.00% | 6.26% | 0.77 | 18.35% | 0.55% | 10.00% | 8.74% | 14.38 | 22.37 | 2.28 | 2.87 |
| MCK | McKesson Corporation | $987.37 | 121.87B | -46% | +187% | — | -38% | 26.01 | -43.65 | 0.25 | 17.57 | 174.88 | -6.68 | 3.48% | 1.22% | 0.92% | -172.11% | 1514.70% | 4.88% | -3.56 | 17.08 | 0.90 | 0.51 | 0.32 | 1487.00% | 1622.00% | 4409.00% | 5.77% | 0.10 | 2267.25% | 0.38% | 9.90% | 5.08% | 21.10 | 17.65 | 0.26 | 5.91 |
| MDT | Medtronic plc | $97.66 | 125.38B | — | -51% | — | -81% | 41.30 | 2.92 | 4.98 | 22.00 | — | -18.12 | 65.19% | 14.89% | 11.97% | — | — | — | 0.51 | 4.85 | 2.65 | 1.91 | 3.03 | — | — | — | 3.26% | 0.73 | — | 2.08% | 86.00% | 2.52% | 36.91 | 33.88 | 5.50 | 3.26 |
| PFE | Pfizer Inc. | $27.65 | 157.21B | +59% | -45% | -66% | -67% | 19.93 | 1.79 | 2.48 | 13.65 | — | -4.02 | 70.33% | 24.67% | 12.42% | 8.90% | 11.33% | 3.69% | 0.75 | 5.78 | 1.16 | 0.37 | 4.22 | -355.00% | -165.00% | -773.00% | 5.86% | 0.32 | 6.66% | 0.00% | 0.00% | 1.48% | 13.35 | 22.71 | 3.29 | 2.12 |
| SNY | Sanofi | $48.66 | 117.52B | -6% | +222% | -59% | +2% | 12.72 | 1.39 | 2.13 | 8.95 | — | 26.05 | 72.34% | 13.58% | 16.72% | 10.50% | 6.06% | 6.02% | 0.31 | 11.73 | 1.09 | 0.28 | 1.11 | -731.00% | 549.00% | 5107.00% | 8.95% | 0.38 | 10.28% | 4.61% | 58.70% | 9.47% | 17.90 | 12.77 | 2.43 | 1.64 |
| SYK | Stryker Corporation | $387.46 | 148.28B | -24% | -56% | — | -59% | 45.57 | 6.60 | 5.89 | 25.13 | 552.53 | -57.96 | 63.96% | 19.47% | 12.92% | 15.08% | 11.08% | 7.15% | 0.66 | 8.05 | 1.89 | 1.04 | 1.72 | 825.00% | 1116.00% | 2283.00% | 2.90% | 0.65 | 13.50% | 0.87% | 39.60% | 0.87% | 32.46 | 37.05 | 6.32 | 4.53 |
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
- CEO
- Michael F. Mahoney
- Employees
- 53K
- Beta
- 0.66
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($50.27 ÷ $56.50) − 1 = -11.03% (DCF, example).